Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketoconazole + tamsulosin is a **combination of two small molecule drugs**: ketoconazole, an imidazole antifungal agent, and tamsulosin, a selective alpha-1 adrenergic receptor antagonist. Ketoconazole inhibits fungal cell membrane synthesis by blocking cytochrome P450 14α-demethylase and also acts as a strong inhibitor of CYP3A4, thus profoundly affecting the metabolism of drugs metabolized by this pathway, including tamsulosin. Tamsulosin works by selectively blocking alpha-1A adrenergic receptors in the prostate and bladder neck, leading to relaxation of smooth muscle and improved urine flow in conditions like benign prostatic hyperplasia (BPH). The combination has been studied for management of acute urinary retention (AUR) due to benign prostatic obstruction (BPO), where the androgen-lowering effects of ketoconazole (rapidly decreasing testosterone) may enhance the efficacy of tamsulosin in enabling successful trial without catheter (TWOC)[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketoconazole + tamsulosin.